This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) shares were unchanged in Copenhagen after the company signed a global exclusive license and collaboration deal worth up to 1.165 billion ($1.3 billion) with Nanexa, a Swedish drug delivery company. Nanexa's Stockholm-listed shares more than doubled in early Friday trading. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The deal gives Novo rights to PharmaShell, Nanexa's platform that coats individual drug particles in an ultra-thin inorganic layer to release them slowly, for certain peptide drugs in obesity, type 2 diabetes and other cardiometabolic diseases.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.